Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22507833 | 0.96 | EGFR (0.43) | EGFRLRRK2MAPTHPGDZAP70 | |
| SCHEMBL26324590 | 0.95 | LRRK2 (0.39) | EGFRLRRK2MAPTHPGDZAP70 | |
| SCHEMBL26324473 | 0.92 | LRRK2 (0.39) | EGFRLRRK2PTK2LMNAKMT2A | |
| SCHEMBL26324859 | 0.88 | LRRK2 (0.37) | EGFRLRRK2ZAP70 | |
| SCHEMBL26324982 | 0.87 | ZAP70 (0.46) | EGFRLRRK2ZAP70 | |
| SCHEMBL26324704 | 0.86 | LRRK2 (0.40) | EGFRLRRK2PTK2 | |
| SCHEMBL23761671 | 0.86 | EGFR (0.54) | EGFRLRRK2MAPTHPGD | |
| SCHEMBL31630575 | 0.86 | EGFR (0.54) | EGFRLRRK2MAPTHPGD | |
| SCHEMBL26324812 | 0.83 | LRRK2 (0.40) | EGFRLRRK2PTK2KMT2A | |
| SCHEMBL26324558 | 0.83 | EGFR (0.48) | EGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | EGFR 5/4885LRRK2 225/4885MAPT 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.